tracxn research — immuno-oncology landscape, september 2016
TRANSCRIPT
Immuno-Oncology Report, September 2016
TracxnWorld’s Largest Startup Research Platform
2
Immuno-Oncology Report, September 20163
Contents
Topic Page No.
Scope of Report 05
Entrepreneur Activity 07
Investment Trend 09
Who is Investing 17
Exit Outlook - IPO, Acquisitions 21
Sub Sector Analysis 24
Interesting Companies 42
Company List 49
Team 154
Immuno-Oncology Report, September 20164
Illustrative Sectors We Track
ENTERPRISEINFRASTRUCTURE
TECH
SECURITY
STORAGE
NETWORKING
MOBILITY
IT OPS
CLOUD INFRASTRUCTURE
API MANAGEMENT
BIGDATA INFRASTRUCTURE
INTERNET OF THINGS
3D PRINTING
HEALTH
EDUCATION
BIOPHARMA
DIAGNOSTICS
MEDICAL DEVICES
HEALTHCARE ANALYTICS
FITNESS AND WELLNESS
HEALTH IT
CONSUMER HEALTHTECH
MOBILE HEALTH
EDUCATION IT
SELF LEARNING
ENTERPRISEAPPLICATIONS
MOBILE
SAAS
MOBILE-FIRST ENT. APPS
INTELLIGENT ENT. APPS
OPEN SOURCE
RETAIL TECH
MARKETING TECH
STEALTH MODE
VERTICAL SAAS
MOBILE COMMERCE
MOBILE PAYMENTS
CONSUMER
FINTECH
MARKETPLACES
SUBSCRIPTION COMM.
UBER FOR X
INTERNET FIRST BRANDS
FOOD TECH
GROCERY TECH
TRAVEL
GAMING
BITCOIN
PAYMENTS
Immuno-Oncology Report, September 20165
Sector Overview
Scope of report
The report contains companies which are developing therapeutics to suppress or activate immune system for the treatment ofcancer. This includes all the companies which are developing antibodies, small molecules, vaccines, viral and adoptive celltherapies for cancer. The report excludes big pharma companies, contract services providers and platform companies.
For funding, this report only includes venture capital/ private equity funding rounds and excludes debt financing andgrants/prize money.
The scope of this report includes equity as well as debt funding received by the companies.
5
Immuno-Oncology Report, September 2016
Scope of Report
Entrepreneur Activity
Investment Trend
Who is Investing
Exit Outlook - IPO, Acquisitions
Sub Sector Analysis
Interesting Companies
Company List
Team
6
Immuno-Oncology Report, September 2016
25
20
24
27
22
37
8
0
8
16
24
32
40
2010 2011 2012 2013 2014 2015 2016
Nu
mb
er o
f C
om
pan
ies
7
YoY – Number of companies founded
BeiGene Panacela Labs ADC Therapeutics Juno Therapeutics Corvus Pharmaceuticals Gritstone Oncology Hengrui Therapeutics
PsiOxus Therapeutics TG Therapeutics Armo BioSciences Jounce Therapeutics Unum Therapeutics Autolus Cell Design Labs
Immuno-Oncology Report, September 2016
Scope of Report
Entrepreneur Activity
Investment Trend
Who is Investing
Exit Outlook - IPO, Acquisitions
Sub Sector Analysis
Interesting Companies
Company List
Team
8
8
Immuno-Oncology Report, September 20169
YoY – Number of Rounds and Total Funding
Note: The funding includes debt rounds also.
$0.5B$0.7B
$1.2B
$0.7B $0.7B
$1.6B
$2.2B
$4.1B
$1.7B
25
72
101
74 73
100
133
129
79
0
28
56
84
112
140
0.0
0.9
1.8
2.7
3.6
4.5
2008 2009 2010 2011 2012 2013 2014 2015 2016
Nu
mb
er of R
ou
nd
sFu
nd
ing
Am
ou
nt
(in
Bill
ion
s)
Funding Amount Number of Rounds
Immuno-Oncology Report, September 201610
YoY – Number of Rounds by Stage
Immuno-Oncology Report, September 201611
YoY – Funding by Stage
Immuno-Oncology Report, September 201612
Average Ticket Size – Early Stage
Immuno-Oncology Report, September 201613
Top investments in last one year
Immuno-Oncology Report, September 201614
Top investments in last one year
Immuno-Oncology Report, September 201615
Funnel view of Sector
Immuno-Oncology Report, September 2016
Scope of Report
Entrepreneur Activity
Investment Trend
Who is Investing
Exit Outlook - IPO, Acquisitions
Sub Sector Analysis
Interesting Companies
Company List
Team
16
16
Immuno-Oncology Report, September 201617
Most Active Investors in Sector
29
2120 20
1514 14 14
1312
0
7
14
21
28
35
Orbimed MPM Capital Alta Partners Novo A/S NovartisVenture Fund
5AM Ventures KPCB Versant Ventures SVLife Sciences
SofinnovaVentures
Tota
l Nu
mb
er o
f R
ou
nd
s
Alpine Immune Sciences
Oncorus Allakos Corvus Pharmaceuticals Adicet Bio Ideaya Biosciences Cell Design Labs Gritstone Oncology DelenexCheckmate
Pharmaceuticals
Armo BioSciencesAmphivena Therapeutics
Kite Pharma Allakos IFM Therapeutics Igenica Zai Lab Nouscom NKT Therapeutics NextCure
Immuno-Oncology Report, September 201618
Where are Top Investors investing
Immuno-Oncology Report, September 201619
Top Investor by Stage of Entry
Immuno-Oncology Report, September 2016
Scope of Report
Entrepreneur Activity
Investment Trend
Who is Investing
Exit Outlook - IPO, Acquisitions
Sub Sector Analysis
Interesting Companies
Company List
Team
20
20
Immuno-Oncology Report, September 201621
Top IPOs in last three years
Immuno-Oncology Report, September 201622
Major Acquisitions in last one year
Immuno-Oncology Report, September 2016
Scope of Report
Entrepreneur Activity
Investment Trend
Who is Investing
Exit Outlook - IPO, Acquisitions
Sub Sector Analysis
Interesting Companies
Company List
Team
23
23
Immuno-Oncology Report, September 201624
September 2016Tracxn BlueBox : Immuno-Oncology 400+ companies in the sector, 343 funded in last 5 years, over $5.7B invested in 2015-16
Immuno-Oncology Report, September 201625
Top Business Models by Funding
$6.5B
$1.5B $1.5B$1.1B
$536M $425M $264M $131M
0
1400
2800
4200
5600
7000
Antibody Adoptive Cell Therapy Vaccine Suite Oncolytic Virus Small Molecule Cytokines Others
Tota
l Fu
nd
ing
Am
ou
nt
(in
Mill
ion
s)
# Cos. 174 30 95 31 28 20 7 16
Avg. Age 2005.8 2009.5 2005.7 2006.8 2007.9 2008.8 2002.9 2005.8
Stemcentrx NantKwest CureVac Immatics BioVex Syndax IRX Therapeutics Iconic Therapeutics
Symphogen Juno Therapeutics Argos Therapeutics BeiGene PsiOxus Therapeutics VentiRx Armo BioSciences Molecular Templates
Immuno-Oncology Report, September 2016
Antibody – Business Model Description
26
Immuno-Oncology Report, September 201627
Antibody – Entrepreneur Activity and Investment Trend
Immuno-Oncology Report, September 201628
Antibody – Most Funded Companies
Immuno-Oncology Report, September 2016
Adoptive Cell Therapy – Business Model Description
29
Immuno-Oncology Report, September 201630
Adoptive Cell Therapy – Entrepreneur Activity and Investment Trend
Immuno-Oncology Report, September 201631
Adoptive Cell Therapy – Most Funded Companies
Immuno-Oncology Report, September 201632
Vaccine – Business Model Description
32
Immuno-Oncology Report, September 201633
Vaccine – Entrepreneur Activity and Investment Trend
Immuno-Oncology Report, September 201634
Adoptive Cell Therapy – Most Funded Companies
Immuno-Oncology Report, September 201635
Suite – Business Model Description
35
Immuno-Oncology Report, September 201636
Suite – Entrepreneur Activity and Investment Trend
Immuno-Oncology Report, September 201637
Suite – Most Funded Companies
Immuno-Oncology Report, September 201638
Oncolytic Virus – Business Model Description
38
Immuno-Oncology Report, September 201639
Oncolytic Virus – Entrepreneur Activity and Investment Trend
Immuno-Oncology Report, September 201640
Oncolytic Virus – Most Funded Companies
Immuno-Oncology Report, September 2016
Scope of Report
Entrepreneur Activity
Investment Trend
Who is Investing
Exit Outlook - IPO, Acquisitions
Sub Sector Analysis
Interesting Companies
Company List
Team
41
Immuno-Oncology Report, September 201642
Interesting Unfunded Companies
Company Overview Business Model
immunophotonics.comAurora Biopharma
(2016, Miami)CAR T cell based immunotherapies for solid cancers. Adoptive Cell Therapy > T Cell
batubiologics.comChestnut Pharmaceuticals
(2015, Toronto)
Developing novel therapeutics for metastatic cancers employing a comprehensive approach to reverse the metastatic state of tumor cells.
Antibody > Tumor-targeting
affinicon.comAR Pharma
(2015, Woburn)Monoclonal antibody to treat B-cell chronic lymphocytic leukemia Antibody > Suite
AngioClast(2015, Cambridge (UK))
Developing antibody drug conjugate for treatment of Glioblastoma multiforme.Antibody > Tumor-targeting > Antibody Drug Conjugates
GO Therapeutics(2013, Cambridge (US))
Developing tumor-specific antibodies for cancer immunotherapy based on cancer glycoproteome.
Antibody > Tumor-targeting
Curated list of companies by the sector analyst are defined as Interesting
Immuno-Oncology Report, September 201643
Interesting Seed Companies
Immuno-Oncology Report, September 201644
Interesting Series A Companies
Immuno-Oncology Report, September 201645
Interesting Series B Companies
Immuno-Oncology Report, September 201646
Interesting Late Stage Companies
Immuno-Oncology Report, September 201647
Top Funded Deadpooled Companies
Immuno-Oncology Report, September 2016
Scope of Report
Entrepreneur Activity
Investment Trend
Who is Investing
Exit Outlook - IPO, Acquisitions
Sub Sector Analysis
Interesting Companies
Company List
Team
4848
Immuno-Oncology Report, September 201649
Immuno-Oncology – Company List
COVERS THE FOLLOWING SECTORS
Small Molecule
Cytokines Antibody VaccineOncolytic
VirusAdoptive Cell
TherapyOthers Suite
Immuno-Oncology Report, September 201650
Small Molecule (1/6)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Company Details Funding Investors
Immunosuppressive Pathway Inhibitors
Syndax [Waltham, 2005]: Syndax is a late-stage biopharmaceutical company developing entinostat as acombination therapy in multiple cancer indications with an initial focus on tumors that have shownsensitivity to immunotherapy, including lung cancer, melanoma and triple negative breast cancer. Entinostat(phase3, breast cancer), its lead drug candidate is an oral, small molecule that has direct effects on bothcancer cells and immune regulatory cells, potentially enhancing the body's immune response to tumors.
$158.65M
Fidelity Investments, Orbimed, Avalon Ventures, MPM Capital, Domain
Associates, Pappas Ventures, Forward Ventures, Tavistock Group, Jennison
Associates, Arrowpoint Partners, RusnanoMedInvest, Delos Capital,
EcoR1, Pappas Capital
Immunosuppressive Pathway Inhibitors
Flexus Biosciences [San Carlos, 2013]: Flexus Biosciences focuses on small-molecule cancerimmunotherapies: IDO & TDO Inhibitors (Immune Response Checkpoint Modulators) that target regulatory Tcells. The company utilizes immunology techniques to identify Agents for Reversal of TumorImmunosuppression (ARTIS). Flexus has a proprietary IDO/TDO discovery program which includes its IDO-selective, IDO/TDO dual and TDO-selective compound libraries. Cancer cells use IDO and TDO pathways tosuppress the host’s immune response in order to facilitate survival, growth, invasion, and metastasis ofmalignant cells. The company has been acquired by Bristol-Myers Squibb on Feb 2015 ($800M upfront and$450M in milestone payments).
$47MKPCB, The Column Group, Celgene,
The Column Group
Immunosuppressive Pathway Inhibitors
Ideaya Biosciences [San Francisco, 2015]: Ideaya Biosciences is an oncology-focused company committed tothe discovery of personalized synthetic lethality medicines targeting DNA damage and repair for geneticallydefined patient populations and immuno-oncology therapies targeting the tumor microenvironment.Synthetic lethality is a phenomenon where the independent loss-of-function of two different genes have nosignificant effects on cell growth and viability, but when combined results in robust cell death. It will focuson novel synthetic lethal interactions for genetically defined patient populations, exploiting inherent tumorsusceptibilities en-route to discovery and development of small-molecule agents to treat major humancancers. It also focusses on modulating DNA repair to augment response to immunotherapy. In addition,drug discovery programs will target pathways known to produce an immune suppressed tumormicroenvironment, enabling tumors to escape recognition by the host immune system.
$46M
Canaan Partners, Celgene, 5AM Ventures, Alexandria Real Estate Equities, NIBR, WuXi Healthcare
Ventures
Immuno-Oncology Report, September 201651
Small Molecule (2/6)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Company Details Funding Investors
Immunosuppressive Pathway Inhibitors
NewLink Genetics [Ames, 1999]: NewLink Genetics is discovering and developing novel immuno-oncologyproduct candidates using its checkpoint inhibitor platform. The company is developing IDO pathwayinhibitors for the treatment of cancer. The indoleamine 2,3-dioxygenase (IDO) pathway regulates immuneresponse by suppressing T-cell function and enabling local tumor immune escape. It is developing two IDOpathway inhibitors—GDC-0919 (in partnership with Genentech) and indoximod. Indoximod is beingdeveloped in combination with antibodies and chemotherapy for the treatment of breast cancer (Phase 2),pancreatic cancer (Phase 2), glioblastoma (Phase 2), melanoma (Phase 2).
$24.5MIowa Capital Management, Ames
Economic Development Commission
Immunosuppressive Pathway Inhibitors
Confluence Life Sciences [St. Louis, 2010]: Confluence Life Sciences (CLS) is a drug discovery and earlydevelopment company which is focusing on developing kinase inhibitors using its proprietary technology. Itsplatform KINect claims to accelerate the identification of drug candidates targeting active-site cysteine-containing kinases. The platform has a thiol-directed chemical library of protein kinase inhibitors which hasbeen utilized in multiple drug discovery programs. Its internal development pipeline has programs for cancerimmunotherapy and autoimmune diseases (IL-2 Inducible T-Cell Kinase (ITK) / Tyrosine-protein Kinaseinhibitors). It is also developing programs for inflammation and cancer externally in partnership with otherpharmacy companies.
$12.81MBioGenerator, Helix Funds, Missouri Technology, Mercury Fund, Epidarex
Capital, St Louis Arch Angels
Immunosuppressive Pathway Inhibitors
TPP Global Development [Edinburgh, 2008]: IOmet (previously named TPP) is a UK-based preclinical-stagedrug development company focused on cancer immunotherapy and metabolism. IOmet has acomprehensive pipeline of IDO, TDO and dual-acting IDO/TDO inhibitors and novel GLUT1 inhibitors. IOmetis pursuing a number of other undisclosed cancer immunotherapy and cancer metabolism targets, inaddition to a GLUT9 inhibitor program for the treatment of gout. Effective January 11, 2016, IOmet Pharmais a wholly owned subsidiary of Merck & Co., Inc.
$12.2M Scottish Enterprise
Immunosuppressive Pathway Inhibitors
Xios Therapeutics [Boston, 2015]: Xios Therapeutics is a biotechnology company focussed on developingsmall molecule therapies for cancer. It is developing drugs which are capable of preventing tumors fromevading the immune system and targets the immuno-oncology pathways and mechanisms which can be thepotential therapeutic target for cancer treatment.
$6M Sutter Hill Ventures
Immuno-Oncology Report, September 201652
Small Molecule (3/6)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Company Details Funding Investors
Immunosuppressive Pathway Inhibitors
Partikula [Miami, 2013]: Partikula is focused on developing novel mitochondrial-targeted therapeutics foroncology using its chemical engineering technologies. It is developing programs which affect the proteinspresent in and around mitochondria. Its portfolio candidates include KULA 18 and KULA 19 which inhibitspyruvate dehydrogenase kinase (PDK) and Hexokinase respectively; KULA-200, a small peptide targeted toinhibit the anti-apoptotic protein Bcl-2; KULA-300 cancer chemotherapeutics and KULA-101, a tumorMicroenvironment Modifier (TMEM) for cancer immunotherapy. It is planning to begin clinical studies of itslead programs in late 2016.
$5.7M 2M Companies
Immunosuppressive Pathway Inhibitors
ImmunoMet Therapeutics [Houston, 2015]: ImmunoMet Therapeutics (a spinoff of HanAll Biopharma) is adevelopment-stage biotechnology company developing oncology products with a focus on cancermetabolism and immuno-oncology. Its novel technology is designed to disrupt cancer cell growth andenhance anti-cancer immunity and may be used in a broad range of difficult-to-treat cancers. Its lead cancermetabolism compound, IM156, an OXPHOS inhibitor, for the treatment of glioblastoma (brain cancer) isexpected to enter Phase 1 clinical development in the second half of 2016.
$5.2M Mirae Asset
Immunosuppressive Pathway Inhibitors
Aminex Therapeutics [Kenmore, 2009]: Aminex Therapeutics is developing cancer immunotherapies. Thecompany is developing a class of immunotherapies known as suppressor class modulators. Its lead candidatereduces polyamine uptake in cancer cells, which in turn leads to reduction in the number of myeloid-derived suppressor cells. As a result, the innate immune system can then be triggered to attack cancer cells.Its lead candidate AMX-513 consists of two drugs, an FDA approved polyamine synthesis inhibitor (DFMO,difluoromethylornithine) and a novel potent polyamine uptake, or transport, inhibitor (AMXT 1501).
$4M
Immunosuppressive Pathway Inhibitors
Oncofactor [Seattle, 2011]: Oncofactor develops cancer therapeutics that disrupt signaling pathwaysbetween tumors and the immune system. The company is developing an oncology platform to identify andtarget immune modulating proteins deferentially expressed by cancer cells. The company claims thattargeting these oncofactors will reveal cancer to the host immune system and permit clearance by nativeimmunity.
$3.1M
OVP Venture Partners, ARCH Venture Partners, Alexandria Real Estate
Equities, Accelerator, Washington Research Foundation, Amgen
Immuno-Oncology Report, September 201653
Small Molecule (4/6)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 201654
Small Molecule (5/6)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 201655
Small Molecule (6/6)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 201656
Cytokines (1/2)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 201657
Cytokines (2/2)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 201658
Antibody (1/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 201659
Antibody (2/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 201660
Antibody (3/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 201661
Antibody (4/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 201662
Antibody (5/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 201663
Antibody (6/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 201664
Antibody (7/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 201665
Antibody (8/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 201666
Antibody (9/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 201667
Antibody (10/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 201668
Antibody (11/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 201669
Antibody (12/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 201670
Antibody (13/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 201671
Antibody (14/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 201672
Antibody (15/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 201673
Antibody (16/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 201674
Antibody (17/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 201675
Antibody (18/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 201676
Antibody (19/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 201677
Antibody (20/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 201678
Antibody (21/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 201679
Antibody (22/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 201680
Antibody (23/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 201681
Antibody (24/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 201682
Antibody (25/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 201683
Antibody (26/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 201684
Antibody (27/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 201685
Antibody (28/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 201686
Antibody (29/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 201687
Antibody (30/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 201688
Antibody (31/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 201689
Antibody (32/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 201690
Antibody (33/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 201691
Antibody (34/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 201692
Antibody (35/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 201693
Antibody (36/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 201694
Antibody (37/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 201695
Antibody (38/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 201696
Antibody (39/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 201697
Antibody (40/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 201698
Antibody (41/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 201699
Antibody (42/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016100
Antibody (43/43)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016101
Vaccine (1/23)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016102
Vaccine (2/23)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016103
Vaccine (3/23)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016104
Vaccine (4/23)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016105
Vaccine (5/23)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016106
Vaccine (6/23)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016107
Vaccine (7/23)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016108
Vaccine (8/23)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016109
Vaccine (9/23)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016110
Vaccine (10/23)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016111
Vaccine (11/23)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016112
Vaccine (12/23)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016113
Vaccine (13/23)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016114
Vaccine (14/23)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016115
Vaccine (15/23)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016116
Vaccine (16/23)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016117
Vaccine (17/23)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016118
Vaccine (18/23)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016119
Vaccine (19/23)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016120
Vaccine (20/23)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016121
Vaccine (21/23)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016122
Vaccine (22/23)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016123
Vaccine (23/23)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016124
Oncolytic Virus (1/7)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016125
Oncolytic Virus (2/7)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016126
Oncolytic Virus (3/7)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016127
Oncolytic Virus (4/7)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016128
Oncolytic Virus (5/7)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016129
Oncolytic Virus (6/7)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016130
Oncolytic Virus (7/7)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016131
Adoptive Cell Therapy (1/8)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016132
Adoptive Cell Therapy (2/8)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016133
Adoptive Cell Therapy (3/8)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016134
Adoptive Cell Therapy (4/8)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016135
Adoptive Cell Therapy (5/8)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016136
Adoptive Cell Therapy (6/8)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016137
Adoptive Cell Therapy (7/8)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016138
Adoptive Cell Therapy (8/8)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016139
Others (1/5)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016140
Others (2/5)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016141
Others (3/5)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016142
Others (4/5)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016143
Others (5/5)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016144
Suite (1/9)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016145
Suite (2/9)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016146
Suite (3/9)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016147
Suite (4/9)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016148
Suite (5/9)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016149
Suite (6/9)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016150
Suite (7/9)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016151
Suite (8/9)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016152
Suite (9/9)
Small Molecule Cytokines Antibody Vaccine Oncolytic Virus Adoptive Cell Therapy Others Suite
Immuno-Oncology Report, September 2016
Scope of Report
Entrepreneur Activity
Investment Trend
Who is Investing
Exit Outlook - IPO, Acquisitions
Sub Sector Analysis
Interesting Companies
Company List
Team
153
Immuno-Oncology Report, September 2016154
Team
154
Shubham Garg
Analyst, BioPharma
Vikash Peesapati
Lead Analyst, Life Sciences